IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
COVD-19 serological testing
COVID-19
IgG
SARS-CoV-2
immunity
neutralizing antibodies
spike
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
31
03
2022
accepted:
16
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
IgG anti-spike (S) antibodies arise after SARS-CoV-2 infection as well as vaccination. Levels of IgG anti-S are linked to neutralizing antibody titers and protection against (re)infection. We measured IgG anti-S and surrogate neutralizing antibody kinetics against Wild Type (WT) and 4 Variants of Concern (VOC) in health care workers (HCW) 3 and 10 months after natural infection ("infection", n=83) or vaccination (2 doses of BNT162b2) with ("hybrid immunity", n=17) or without prior SARS-CoV-2 infection ("vaccination", n=97). The humoral immune response in the "vaccination" cohort was higher at 3 months, but lower at 10 months, compared to the "infection" cohort due to a faster decline. The "hybrid immunity" cohort had the highest antibody levels at 3 and 10 months with a slower decline compared to the "vaccination" cohort. Surrogate neutralizing antibody levels (expressed as %inhibition of ACE-2 binding) showed a linear relation with log10 of IgG anti-S against WT and four VOC. IgG anti-S corresponding to 90% inhibition ranged from 489 BAU/mL for WT to 1756 BAU/mL for Beta variant. Broad pseudoneutralization predicted live virus neutralization of Omicron BA.1 in 20 randomly selected high titer samples. Hybrid immunity resulted in the strongest humoral immune response. Antibodies induced by natural infection decreased more slowly than after vaccination, resulting in higher antibody levels at 10 months compared to vaccinated HCW without prior infection. There was a linear relationship between surrogate neutralizing activity and log10 IgG anti-S for WT and 4 VOC, although some VOC showed reduced sensitivity to pseudoneutralization.
Sections du résumé
Background
IgG anti-spike (S) antibodies arise after SARS-CoV-2 infection as well as vaccination. Levels of IgG anti-S are linked to neutralizing antibody titers and protection against (re)infection.
Methods
We measured IgG anti-S and surrogate neutralizing antibody kinetics against Wild Type (WT) and 4 Variants of Concern (VOC) in health care workers (HCW) 3 and 10 months after natural infection ("infection", n=83) or vaccination (2 doses of BNT162b2) with ("hybrid immunity", n=17) or without prior SARS-CoV-2 infection ("vaccination", n=97).
Results
The humoral immune response in the "vaccination" cohort was higher at 3 months, but lower at 10 months, compared to the "infection" cohort due to a faster decline. The "hybrid immunity" cohort had the highest antibody levels at 3 and 10 months with a slower decline compared to the "vaccination" cohort. Surrogate neutralizing antibody levels (expressed as %inhibition of ACE-2 binding) showed a linear relation with log10 of IgG anti-S against WT and four VOC. IgG anti-S corresponding to 90% inhibition ranged from 489 BAU/mL for WT to 1756 BAU/mL for Beta variant. Broad pseudoneutralization predicted live virus neutralization of Omicron BA.1 in 20 randomly selected high titer samples.
Conclusions
Hybrid immunity resulted in the strongest humoral immune response. Antibodies induced by natural infection decreased more slowly than after vaccination, resulting in higher antibody levels at 10 months compared to vaccinated HCW without prior infection. There was a linear relationship between surrogate neutralizing activity and log10 IgG anti-S for WT and 4 VOC, although some VOC showed reduced sensitivity to pseudoneutralization.
Identifiants
pubmed: 35784321
doi: 10.3389/fimmu.2022.909910
pmc: PMC9241488
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
909910Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2022 Decru, Van Elslande, Steels, Van Pottelbergh, Godderis, Van Holm, Bossuyt, Van Weyenbergh, Maes and Vermeersch.
Déclaration de conflit d'intérêts
PV reports personal fees from Roche, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Lancet. 2021 Jun 19;397(10292):2331-2333
pubmed: 34090624
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Clin Invest. 2022 Mar 15;132(6):
pubmed: 35139036
Clin Infect Dis. 2021 Nov 16;73(10):1882-1886
pubmed: 33718968
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
EBioMedicine. 2020 Dec;62:103101
pubmed: 33160207
Clin Chim Acta. 2021 Nov;522:144-151
pubmed: 34425105
Clin Infect Dis. 2021 Dec 16;73(12):2366-2368
pubmed: 33693643
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Lancet Infect Dis. 2022 Jan;22(1):12-14
pubmed: 34762853
Eur J Intern Med. 2022 Mar;97:113-115
pubmed: 35012818
Front Immunol. 2022 Mar 24;13:861050
pubmed: 35401572
Sci Immunol. 2022 Feb 18;7(68):eabn8014
pubmed: 35076258
Clin Microbiol Infect. 2022 Jul;28(7):1024.e7-1024.e12
pubmed: 35124261
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
JAMA. 2021 Nov 16;326(19):1930-1939
pubmed: 34724027
Diagn Microbiol Infect Dis. 2022 May;103(1):115659
pubmed: 35278794
Eur Respir J. 2022 Feb 10;59(2):
pubmed: 34446469
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Clin Chem Lab Med. 2021 Sep 08;59(12):1885-1888
pubmed: 34496165
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
Diagn Microbiol Infect Dis. 2022 Apr;102(4):115638
pubmed: 35104720
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Sci Rep. 2021 Aug 30;11(1):17325
pubmed: 34462501
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
J Clin Virol. 2020 Aug;129:104512
pubmed: 32563180
N Engl J Med. 2021 Dec 30;385(27):2585-2586
pubmed: 34910864
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nat Med. 2022 May;28(5):1072-1082
pubmed: 35165453
EBioMedicine. 2021 Nov;73:103677
pubmed: 34742128